
iLet learns from change
iLet learns from glucose patterns and insulin responses every five minutes, refining personalized dosing for basal, corrections, and meals over time.
Explore the iLet Bionic Pancreas in 3D to see its design, key features, and how it works to automate insulin delivery.
Try NowHear from people living with diabetes about their experiences with the iLet Bionic Pancreas and how it fits into their everyday lives.
Read MoreJoin experts and the Beta Bionics team for insights on diabetes management, automated insulin delivery, and the iLet Bionic Pancreas.
Register NowHear from people living with diabetes about their experiences with the iLet Bionic Pancreas and how it fits into their everyday lives.
Read MoreExplore the technology, clinical evidence, and adaptive intelligence behind iLet Bionic Pancreas.
From everyday fluctuations to changing insulin needs over time, the adaptive intelligence behind iLet continuously learns, adapts and keeps up with the individual.

iLet learns from glucose patterns and insulin responses every five minutes, refining personalized dosing for basal, corrections, and meals over time.Read More

Learns and adapts dosing decisions as individual needs evolve, reducing manual adjustments and patient-initiated corrections.Read More

Dosing adapts between visits, your clinical judgment and expertise guide the care.Read More
Life changes. Insulin needs change. iLet keeps up with life.
Backed by 3 years of real world data.
For starting HbA1c from
<7% to >14%1
See real world outcomes for a broader population
HbA1c → GMI Reduction
1.6%1
HbA1c to GMI reduced by an average of 1.6%
Time in Range (70–180 mg/dL)
+25%1
Improvement in continuous glycemic time-in-range, offering patients consistent protection day and night.
Time <54 mg/dL of time
0.27%1
ADA Goal: <1% of time
iLet takes on more of the decisions behind insulin dosing giving patients more freedom from the calculations, settings and dosing decisions that can make diabetes management feel like constant work.
Patients don't have to make dosing decisions, iLet dynamically adapts without the need for correction factors or insulin to carb ratios.
Read MoreiLet continuously determines insulin needs and adapts over time to match the individual's changing physiology-without relying on patient programmed basal rates.
Read MorePatients simply characterize meals as Usual for me, More or Less, rather than calculating exact carbohydrate amounts, while iLet continuously learns and adapts meal doses over time.
Read MoreAdvanced Intelligence determines when additional insulin is needed and delivers the dose autonomously
Read MoreNo diabetes math. More freedom to live.
Adaptive Intelligence takes on more of the dosing decisions so your expertise can shift from programming therapy settings to selecting, supporting, and caring for the person.

Identify appropriate patients, evaluate outcomes and tailor care to individual needs.
Explore patient goals, daily routines and challenges to support whole-person care.
Use Bionic Reports to assess glucose patterns, insulin delivery and patient interactions to guide care.
Rely on iLet to continuously learn and adapt insulin dosing as patient needs evolve, while maintaining clinical oversight.
iLet integrates with compatible continuous glucose monitoring systems to support automated insulin delivery.

Dexcom CGM Systems bring trusted CGM technology together with the iLet Bionic Pancreas for a simple, connected AID experience. Dexcom G7 supports users ages 2+, while Dexcom G7 15 Day offers adults 18+ up to 15 days of wear, plus a 12-hour grace period~.

FreeStyle Libre 3 Plus sensor is the world’s smallest2 15-day CGM sensor for all ages (2+)3, with glucose readings sent automatically every minute to iLet. Together, FreeStyle Libre 3 Plus sensor and iLet create one easy*, single-app experience.

Eversense 365 is the world’s only one-year CGM, delivering exceptional accuracy, including industry-leading accuracy in the low glucose range.4 Together, Eversense 365 and the iLet Bionic Pancreas bring year-long CGM convenience to a simple, connected insulin delivery experience.
From patients who need help reaching their goals to those achieving them with significant daily effort, consider who could benefit from an AID system that continuously adapts to life.

Help newly diagnosed patients reach their glycemic goals with much less mental burden from the start.Read More

Whether on MDI or pump therapy who are not at goal.Read More

Working hard, feeling burnt out from relentless diabetes decision making.Read More
Angela, age 48
"Within 1 week of using iLet Bionic Pancreas, my time in range went from 46% to 82%, and my A1C went from 8.2 to 6.1-I’m in awe!"
Cruz, age 16
"I’m always on the go, so it’s awesome not having to worry about counting carbs. iLet Bionic Pancreas figured me out in only a few days and honestly just takes care of me now. My A1C’s 5.7, and I hardly do anything."
Faith, mom of Piper, age 10
“Piper has her life back. She now has the freedom and independence to be a kid again. And as her parents, it’s given us peace. My kid is safe and healthy. That is everything.”
From prescription through training and ongoing support, Beta Bionics helps your practice and patients get started with iLet.

Identify an appropriate patient and submit the iLet prescription via Parachute, Online Referral or Fax.
Beta Bionics support helps patients and practices navigate coverage, fulfillment and the steps required to move toward start.
Patients receive training and support on meal announcements, system interaction.
Clinical and patient resources help reinforce successful iLet use after initiation.
Easy to initiate. No basal rates. No correction factors. No insulin-to-carb ratios to build.
Just set glycemic target and enter patient body weight to initiate.
Disclaimer:1 Data on file.The post-market surveillance data presented are observational. They do not come from a prospective study designed to evaluate the safety or effectiveness of the iLet Bionic Pancreas. Data come from a real-world population from the first 3 years (5/19/2023-5/19/2026) of iLet usage among users who had baseline HbA1c and/or TIR data available and who uploaded at least two weeks' worth of CGM data to Beta Bionics, Inc., including users who do not meet all criteria in the Indications for Use. Individual user results may vary from the average values shown here. For TIR analyses, data come from current iLet users who have uploaded at least one CGM value to Beta Bionics, Inc. between 3/19/2026 and 5/19/2026.
2 Data on file. Abbott Diabetes Care, Inc.
3 FreeStyle Libre 3 User’s Manual. *Based on sensor features including up to 15-day wear period, automatic readings every minute, accuracy data, and single-app setup with AID systems.
4 Bailey TS, et. al. Evaluation of Accuracy and Safety of the 365-Day Implantable Eversense Continuous Glucose Monitoring System: The ENHANCE Study. Diabetes Technology & Therapeutics. 2025; DOI:10.1089/dia.2024.0592
5 Individual results may vary.
~A study was conducted to assess sensor life, where 73.9% of sensors lasted the full 15 days. When using the product per the package labeling, approximately 26% of sensors may not last for the full 15 days.

Consider the patients in your practice who could benefit from proven glycemic outcomes with less reliance on dosing math, traditional therapy settings and constant dosing decisions